ImmunityBio Announces Database Lock for Registrational Trial of Locally Delivered, Chemotherapy-Free ANKTIVA® Plus BCG in BCG-Naïve Non-Muscle Invasive Bladder Cancer
ImmunityBio completed database lock for Cohort A of QUILT-2.005 (NCT02138734), its registrational trial testing ANKTIVA plus BCG versus BCG alone in 366 patients with BCG-naïve non-muscle invasive bladder cancer. A prior FDA-requested interim analysis showed statistically significant longer duration of complete response for the ANKTIVA combination, and final analysis of the primary endpoint is now underway.
Key figures
- Drug Name
- ANKTIVA (nogapendekin alfa inbakicept-pmln)
- Phase Of Trial
- Registrational (QUILT-2.005, Cohort A)
- Trial id
- NCT02138734
- Clinical sites
- 110
- Sbla submission
- Q4 2026
- Topline results
- November 2026
- Patients randomized
- 366
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.